Metabolic

Genfit announces the release of NASHnext

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Genfit, in partnership with Labcorp, announced the introduction of a non-invasive non-alcoholic steatohepatitis test for high-risk patients, according to a press release.

Using a novel blood-based molecular biomarker test, NASHnext identifies NASH and significant fibrosis in patients with at least one metabolic risk factor. Researchers hope that the widespread availability of this test will enable clearer early diagnosis and make informed decisions about monitoring or slowing the progression of liver disease.

“NASH is a widespread but undiagnosed liver disease with very serious consequences, including end-stage liver disease and cardiovascular events.” Brian Caveney, MD, Chief Medical Ocer and President of Labcorp Diagnostics said in the press release. “NASHnext has the potential to significantly benefit very large patient populations by providing people with vital information about their liver health.”

The test is only offered in the US and Canada through Labcorp.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Related Articles